Ocular Therapeutix™ Announces the Hiring of Chad Brines, Vice President, Sales

BEDFORD, Mass.--(BUSINESS WIRE)--$OCUL #OCUTX--Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the hiring of Chad Brines as Vice President, Sales. Mr. Brines will be responsible for implementing the Company’s commercial strategy and leading the commercial field organization as the Company prepares for the launch of DEXTENZA®. “We are pleased to we

Full Story →